The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. 2006

Eric Lippert, and Marjorie Boissinot, and Robert Kralovics, and François Girodon, and Irène Dobo, and Vincent Praloran, and Nathalie Boiret-Dupré, and Radek C Skoda, and Sylvie Hermouet
Laboratoire d'Hématologie du CHU de Bourdeaux, France.

We determined the allelic frequency of the JAK2-V617F mutation in DNA and assessed the expression levels of the mutant and wild-type JAK2 mRNA in granulocytes from 60 patients with essential thrombocythemia (ET) and 62 patients with polycythemia vera (PV) at the time of diagnosis. Using allele-specific quantitative polymerase chain reaction (qPCR), we detected JAK2-V617F in 75% of ET and 97% of PV at diagnosis. The total JAK2 mRNA levels were elevated in ET, PV, and secondary and idiopathic erythrocytosis, suggesting that hyperactive hematopoiesis alters JAK2 expression. The expression levels of JAK2-V617F mRNA were variable but strongly correlated with the allelic ratio of JAK2-V617F determined in DNA. Thus, differences in JAK2-V617F expression, markedly lower in ET than in PV, reflected different percentages of granulocytes carrying the mutation. Moreover, allelic ratios higher than 50% JAK2-V617F, indicating the presence of granulocytes homozygous for JAK2-V617F, were found in 70% of PV at diagnosis but never in ET.

UI MeSH Term Description Entries
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D011087 Polycythemia Vera A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs. Erythremia,Osler-Vaquez Disease,Polycythemia Rubra Vera,Polycythemia Ruba Vera,Primary Polycythemia,Disease, Osler-Vaquez,Erythremias,Osler Vaquez Disease,Polycythemia Ruba Veras,Polycythemia Rubra Veras,Polycythemia, Primary,Polycythemias, Primary,Primary Polycythemias,Ruba Vera, Polycythemia,Ruba Veras, Polycythemia,Vera, Polycythemia Ruba,Vera, Polycythemia Rubra,Veras, Polycythemia Ruba,Veras, Polycythemia Rubra
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D005787 Gene Frequency The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION. Allele Frequency,Genetic Equilibrium,Equilibrium, Genetic,Allele Frequencies,Frequencies, Allele,Frequencies, Gene,Frequency, Allele,Frequency, Gene,Gene Frequencies
D006098 Granulocytes Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS. Granulocyte
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000483 Alleles Variant forms of the same gene, occupying the same locus on homologous CHROMOSOMES, and governing the variants in production of the same gene product. Allelomorphs,Allele,Allelomorph
D001483 Base Sequence The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence. DNA Sequence,Nucleotide Sequence,RNA Sequence,DNA Sequences,Base Sequences,Nucleotide Sequences,RNA Sequences,Sequence, Base,Sequence, DNA,Sequence, Nucleotide,Sequence, RNA,Sequences, Base,Sequences, DNA,Sequences, Nucleotide,Sequences, RNA

Related Publications

Eric Lippert, and Marjorie Boissinot, and Robert Kralovics, and François Girodon, and Irène Dobo, and Vincent Praloran, and Nathalie Boiret-Dupré, and Radek C Skoda, and Sylvie Hermouet
April 2008, Leukemia & lymphoma,
Eric Lippert, and Marjorie Boissinot, and Robert Kralovics, and François Girodon, and Irène Dobo, and Vincent Praloran, and Nathalie Boiret-Dupré, and Radek C Skoda, and Sylvie Hermouet
September 2008, International journal of hematology,
Eric Lippert, and Marjorie Boissinot, and Robert Kralovics, and François Girodon, and Irène Dobo, and Vincent Praloran, and Nathalie Boiret-Dupré, and Radek C Skoda, and Sylvie Hermouet
September 2012, Molecular biology reports,
Eric Lippert, and Marjorie Boissinot, and Robert Kralovics, and François Girodon, and Irène Dobo, and Vincent Praloran, and Nathalie Boiret-Dupré, and Radek C Skoda, and Sylvie Hermouet
January 2007, Haematologica,
Eric Lippert, and Marjorie Boissinot, and Robert Kralovics, and François Girodon, and Irène Dobo, and Vincent Praloran, and Nathalie Boiret-Dupré, and Radek C Skoda, and Sylvie Hermouet
February 2022, American journal of hematology,
Eric Lippert, and Marjorie Boissinot, and Robert Kralovics, and François Girodon, and Irène Dobo, and Vincent Praloran, and Nathalie Boiret-Dupré, and Radek C Skoda, and Sylvie Hermouet
May 2009, Clinical advances in hematology & oncology : H&O,
Eric Lippert, and Marjorie Boissinot, and Robert Kralovics, and François Girodon, and Irène Dobo, and Vincent Praloran, and Nathalie Boiret-Dupré, and Radek C Skoda, and Sylvie Hermouet
April 2007, The Korean journal of laboratory medicine,
Eric Lippert, and Marjorie Boissinot, and Robert Kralovics, and François Girodon, and Irène Dobo, and Vincent Praloran, and Nathalie Boiret-Dupré, and Radek C Skoda, and Sylvie Hermouet
December 2021, Blood research,
Eric Lippert, and Marjorie Boissinot, and Robert Kralovics, and François Girodon, and Irène Dobo, and Vincent Praloran, and Nathalie Boiret-Dupré, and Radek C Skoda, and Sylvie Hermouet
April 2022, Blood cancer journal,
Eric Lippert, and Marjorie Boissinot, and Robert Kralovics, and François Girodon, and Irène Dobo, and Vincent Praloran, and Nathalie Boiret-Dupré, and Radek C Skoda, and Sylvie Hermouet
August 2010, Haematologica,
Copied contents to your clipboard!